Summary by Futu AI
Recursion Pharmaceuticals announced the release of an updated investor presentation on January 13, 2025, to be presented at the JP Morgan Healthcare Conference. The company showcased its robust pipeline of 10 clinical and pre-clinical programs across oncology, rare diseases, and other high-unmet need areas.The presentation highlighted significant partnership achievements, including four large pharma collaborations that have earned approximately $450M in upfront and milestone payments to date, with potential for over $20B in additional milestone payments. The company's portfolio includes ~10 clinical program milestones expected over the next 18 months.Recursion's unified Operating System (OS) demonstrates both first and best-in-class capabilities, supporting approximately 10 additional advanced discovery programs and over 10 partnered programs. The company's focus spans oncology, immunology, and other areas of high unmet medical need.
Comment(0)
Reason For Report